Lens Clarity After 3-Port Lens-Sparing Vitrectomy in Stage 4A and 4B Retinal Detachments Secondary to Retinopathy of Prematurity

Plasmin Enzyme-Assisted Vitrectomy in Pediatric Patients with Vitreoretinal Diseases

“…However, these complications are also common after vitrectomy. Lens opacities after lens-sparing vitrectomy for advanced ROP have been reported in about 5-15% of cases [35,36]. The higher rate of cataract formation in our participants compared with lens-sparing vitrectomy may be related to several factors.…”

Long-term Outcomes on Lens Clarity after Lens-Sparing Vitrectomy for Retinopathy of Prematurity

“…10e12 Lens opacities after LSV for advanced ROP have been reported to occur in a minority of cases, ranging from 5% to 37%, with a higher incidence in those with more advanced disease. 13,14 Lens clarity has been demonstrated previously in most eyes after LSV, with an average follow-up of 2 to 3 years. 13,14 In adults, vitrectomy surgery has been associated with the acceleration of nuclear sclerosis in 60% to 98% of eyes within 2 years.…”

“…13,14 Lens clarity has been demonstrated previously in most eyes after LSV, with an average follow-up of 2 to 3 years. 13,14 In adults, vitrectomy surgery has been associated with the acceleration of nuclear sclerosis in 60% to 98% of eyes within 2 years. 15e17 It has been postulated that the pediatric lens is more resistant to cataract formation because of a relative increased capacity to metabolize oxygen radicals.…”

“…These data are consistent with the results of previously published reports, which when combined show an average of 15.6% of eyes demonstrating lens opacities after LSV, with an average follow-up of 2.43 years (range, 2.25e2.9 years). 13,14 Several factors may contribute to the maintenance of lens clarity in children. First, there is a relative increased metabolic activity of the lens cortex in youth.…”

Efficacy of Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents for Stage 4 Retinopathy of Prematurity

“…[6][7][8] However, the adverse events such as endophthalmitis, cataract, delayed-onset intraocular pressure elevation, refractive error, and the need for division (or removal) of the encircling element for the growing eye may evolve. [8][9][10][11][12][13] Treatment with intravitreal bevacizumab (IVB) (Avastin; Genentech Inc, South San Francisco, CA), a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, is an emerging modality for ROP, with significant treatment effect and better preservation of the peripheral retina compared with conventional laser treatment for Stage 3+ ROP. 14 Significantly elevated vitreous VEGF levels have been identified in vascular-active Stage 4 ROP, and few case series have mentioned IVB for patients with a more advanced stage of ROP.…”